
---
title: '美诺华：子公司缬沙坦原料药通过CDE技术审评'
categories: 
 - 金融
 - 证券时报网
 - 快讯
headimg: 'https://picsum.photos/400/300?random=3912'
author: 证券时报网
comments: false
date: Mon, 30 May 2022 20:48:00 GMT
thumbnail: 'https://picsum.photos/400/300?random=3912'
---

<div>   
<p>证券时报e公司讯，<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SS603538" style="color: #2f67d1;text-decoration: none;" code="603538" target="_blank">美诺华</a>(603538)5月30日晚间公告，控股子公司安徽<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SS603538" style="color: #2f67d1;text-decoration: none;" code="603538" target="_blank">美诺华</a>缬沙坦原料药通过CDE技术审评。药品适用于治疗高血压症、充血性心力衰竭、后心肌梗塞。缬沙坦原料药通过CDE技术审评，表示其可销售至国内市场。</p>

                  
</div>
            